VNDA Vanda Pharmaceuticals Inc.

26.24
+0.09  (+0%)
Previous Close 26.15
Open 26.01
Price To Book 5.27
Market Cap 1376284851
Shares 52,449,880
Volume 470,766
Short Ratio
Av. Daily Volume 764,694

NewsSee all news

  1. The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
  2. How Does Investing In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Impact The Volatility Of Your Portfolio?
  3. 4 Stocks That Had Massive Earnings Surprises in 2018
  4. Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome
  5. Inovio (INO) to Receive Milestone Payment From AstraZeneca

SEC filingsSee all SEC filings

  1. 8-K - Current report 181226523
  2. 8-K - Current report 181214351
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167281
  4. 8-K - Current report 181166306
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181116264

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 primary endpoint met - December 3, 2018.
Tradipitant
Gastroparesis
PK trial initiated with full enrollment completed 4Q 2017.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
Phase 2 data released March 5, 2018 - primary endpoint met.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 data released December 10, 2018 - one of two primary endpoints met.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 3 trial initiated June 2018.
Tradipitant
Atopic dermatitis
Phase 1 initiated October 2018.
VTR-297
Hematologic malignancies

Latest News

  1. The Zacks Analyst Blog Highlights: Vanda Pharmaceuticals, Penumbra, G-III Apparel and General Finance
  2. How Does Investing In Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Impact The Volatility Of Your Portfolio?
  3. 4 Stocks That Had Massive Earnings Surprises in 2018
  4. Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome
  5. Inovio (INO) to Receive Milestone Payment From AstraZeneca
  6. Amgen's BiTE Immunotherapies Show Promise in Early Studies
  7. Company News For Dec 4, 2018
  8. The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
  9. FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate
  10. Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis
  11. Zacks.com highlights: Vericel, Mitek, Vanda Pharmaceuticals, Mosaic and Spirit Airlines
  12. 5 Stocks With Recent Price Strength to Strengthen Portfolio
  13. Edited Transcript of VNDA earnings conference call or presentation 7-Nov-18 9:30pm GMT
  14. Earnings Estimates Moving Higher for Vanda (VNDA): Time to Buy?
  15. Vanda Pharmaceuticals Announces Participation at November 2018 Investor Conferences
  16. This Biotech Stock Briefly Edged Into Buy Zone On Earnings Crush
  17. Vanda Pharmaceuticals (VNDA) Surpasses Q3 Earnings and Revenue Estimates
  18. Vanda: 3Q Earnings Snapshot
  19. Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results
  20. The FDA is cracking down on a local drugmaker. The company isn't completely sure why.

SEC Filings

  1. 8-K - Current report 181226523
  2. 8-K - Current report 181214351
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181167281
  4. 8-K - Current report 181166306
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 181116264
  6. 8-K - Current report 181108192
  7. 8-K - Current report 181018964
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986603
  9. 8-K - Current report 18985017
  10. S-8 - Securities to be offered to employees in employee benefit plans 18896806